A Clinical Trial to Study the Effects of Revamilast in Patients With Chronic Persistent Asthma
A Phase II, 12-week Randomized, Double-blind, Triple Dummy, Parallel Group, Placebo-controlled, Dose Range Finding Study to Evaluate Safety, Tolerability and Efficacy of Revamilast in Patients With Chronic Persistent Asthma
Sponsor: Glenmark Pharmaceuticals Ltd. India
A PHASE2 clinical study on Asthma, this trial is completed. The trial is conducted by Glenmark Pharmaceuticals Ltd. India and has accumulated 6 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Oct 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Glenmark Pharmaceuticals Ltd. India
- Glenmark Pharmaceuticals S.A.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ahmedabad, India, Bangalore, India, Bialystok, Poland, Brno, Czechia, Chennai, India, Elektrostal, Russia, Gdansk, Poland, Hyderabad, India, Indore, India, Jaipur, India and 22 more location s